The newly shipped HCI as an injection is the generic form of CellCept, which is a registered trademark of Hoffman-LaRoche Inc. With its release, Par’s HCI as an injection is the first and the only generic injection on the market at this time. In a 12-month period that ended Oct. 31, CellCept’s sales in the U.S. were approximately $42 million. These numbers are according to data from IMS Health.
HCI as an injection will be sold in four 500 mg single dose vials per carton.
Alerts Sign-up